top of page

Treprostinil benefits PAH patients with cardiovascular issues

PHA Canada

Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new analysis of data from two clinical trials indicated that treprostinil (Remodulin) in addition to existing treatment was safe and effective in preventing clinical worsening for these patients.


Recent Posts

Comments


PHA Canada

408 - 55 Water Street

Office 8928

Vancouver, BC, V6B 1A1

Email: info@phacanada.ca

Phone: 604-682-1036

Toll Free: 1-877-774-2226

  • Instagram
  • Facebook
  • X
  • LinkedIn
  • Youtube

Copyright 2024 PHA CANADA, ALL RIGHTS RESERVED   |   Website created by Creativibe   |   Powered by raisin

bottom of page